Advances in lymphoma biomarkers research based on proteomics technology (Review)

Lymphoma is a common malignancy characterized by diverse pathological types and marked heterogeneity. Distinct subtypes of lymphomas are markedly different in their clinical manifestations, treatment approaches and prognostic outcomes. With the rapid development of molecular biology techniques, antitumor research has stepped into an era of precision medicine. Biomarkers, with high sensitivity and specificity, are expected to function in early diagnosis, targeted treatment and prognostic estimation for cancer and enhance the survival rate and life quality of patients. In this regard, proteomics technology, with the capability to systematically identify and quantify the dynamic protein alterations in tissues or cells, thereby facilitating the discovery of novel tumor potential candidates, has attracted significant scientific attention. The present article aimed to review most up‑to‑date research progress of lymphoma‑related biomarkers discovered based on proteomics technology, focusing on the potential application of these markers in the diagnosis, therapy and prognosis of each lymphoma subtype, and discuss the role proteomics may serve in future development of lymphoma research and clinical practice.